In Northern California and beyond, health care systems are rapidly integrating artificial intelligence (AI) and digital tools to transform how pain is recognized, measured, and managed. From algorithm-guided assessments to wearable sensors and predictive analytics, these tools promise to augment clinical decision-making and improve patient outcomes. Yet significant controversies remain, including concerns over algorithmic accuracy, bias, data privacy, and the extent to which technology should complement or potentially displace human clinical judgment.
The promise of AI in pain assessment
Pain assessment has historically relied on subjective reports, such as numeric scales or clinician interpretation of patient behaviors. AI offers the possibility of objective, data-driven evaluation by analyzing physiological signals, facial expressions, electronic health record data, and even wearable device outputs to identify pain status more consistently than traditional methods.
Reviews of existing research indicate that machine learning and natural language processing can enhance pain recognition, assist clinicians in predicting pain trajectories, and support self-management strategies, although most studies remain preliminary pilot projects rather than large clinical trials.
Clinical initiatives have already begun experimenting with automated pain recognition systems, for example, combining computer vision and deep learning to interpret facial cues during perioperative care.
Accuracy and algorithmic bias: a central controversy
One of the most debated challenges is whether AI tools can be accurate and equitable. Algorithms are only as good as the data on which they are trained, and pain datasets often lack diversity. Underrepresentation of various demographic groups, such as older adults, people of color, and women, can lead to models that perform well in some populations but poorly in others.
Recent research using synthetic, demographically balanced datasets illustrates both the potential to improve fairness in pain detection and the persistent risk of performance disparities across age, ethnicity, and gender groups.
Moreover, health care AI more broadly has faced criticism for downplaying symptoms in women and ethnic minorities, raising fears that these tools might unintentionally perpetuate existing health disparities rather than reduce them. Civil rights advocacy organizations are now pushing for “equity-first” standards in the development and deployment of medical AI to prevent bias from being baked into clinical decision tools.
Data privacy and regulatory gaps
AI-driven pain assessment requires large quantities of sensitive data, mainly from electronic health record (EHR) histories to real-time biometric monitoring. While these data are essential for predictive power, they also create risks related to privacy, security, and governance. Without robust data governance frameworks, patients may be exposed to unauthorized access or misuse of their health information, undermining trust and potentially violating privacy laws, which need to be respected and protected.
Real-world anecdotes from U.S. health care technology forums underscore how easily non-compliant AI tools can be used in clinical settings, potentially exposing protected health information and creating liability concerns.
Industry observers also note that inconsistent regulatory oversight, especially for tools deployed outside traditional FDA review pathways, can leave clinicians and health systems responsible for judging the safety and efficacy of digital pain assessment tools on their own.
Transparency, trust, and “black box” challenges
AI systems, especially complex deep learning models, are often described as “black boxes,” with limited transparency in how inputs generate outputs. For both clinicians and patients, understanding why an AI tool made a specific recommendation is crucial to building trust and ensuring responsible use in high-stakes clinical contexts.
Lack of interpretability can undermine the patient-provider relationship, especially if AI outputs contradict patient narratives or clinical intuition. Solutions such as explainable AI frameworks and clinician training programs have been proposed to bridge this gap, ensuring that AI acts as a supportive tool, not an opaque authority.
Human oversight and clinical judgment
Perhaps the most fundamental debate is whether AI should augment or replace aspects of human clinical judgment. Pain is deeply subjective, influenced by psychosocial factors that are not easily reduced to physiological metrics or algorithmic output. Many ethicists and clinicians argue that AI must remain firmly in the service of human decision-making, preserving empathy, patient voice, and context.
Emerging frameworks for responsible AI emphasize collaboration between clinicians and algorithmic tools, ensuring clinicians retain authority while AI provides data insights, flagging patterns that might otherwise go unnoticed.
Conclusion: Toward balanced innovation
AI and digital tools hold significant promise for transforming pain assessment, from improving objectivity, reducing clinician burden, and supporting personalized care, to potentially uncovering patterns that escape traditional evaluation. At the same time, controversies around bias, privacy, interpretability, and clinical integration must be addressed with transparent governance, inclusive datasets, regulatory clarity, and ongoing ethical scrutiny.
As Northern California’s leading health systems and research institutions continue to pilot these technologies, the broader pain management community must engage in thoughtful, interdisciplinary dialogue to ensure that innovation enhances equity, amplifies patient voices, and upholds the highest standards of clinical care.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
